Day One Biopharmaceuticals Inc (NASDAQ: DAWN) is -3.22% lower on its value in year-to-date trading and has touched a low of $9.67 and a high of $18.07 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DAWN stock was last observed hovering at around $13.67 in the last trading session, with the day’s gains setting it 0.46%.
Currently trading at $14.13, the stock is 0.73% and -1.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing 3.37% at the moment leaves the stock -2.45% off its SMA200. DAWN registered -4.91% loss for a year compared to 6-month loss of -0.42%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 5.37% gain in the last 1 month and extending the period to 3 months gives it a 9.37%, and is -0.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.81% over the week and 4.24% over the month.
Day One Biopharmaceuticals Inc (DAWN) has around 155 employees, a market worth around $1.24B and $8.19M in sales. Profit margin for the company is -2044.43%. Distance from 52-week low is 46.12% and -21.80% from its 52-week high. The company has generated returns on investments over the last 12 months (-54.60%).
The EPS is expected to grow by 17.67% this year.
Day One Biopharmaceuticals Inc (DAWN) Top Institutional Holders
234.0 institutions hold shares in Day One Biopharmaceuticals Inc (DAWN), with institutional investors hold 108.27% of the company’s shares. The shares outstanding are 87.23M, and float is at 59.29M with Short Float at 23.74%. Institutions hold 87.05% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 7.87 million shares valued at $108.47 million. The investor’s holdings represent 9.0814% of the DAWN Shares outstanding. As of 2024-06-30, the second largest holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with 6.43 million shares valued at $88.61 million to account for 7.4184 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 4.62 million shares representing 5.3338% and valued at over $63.71 million, while BLACKROCK INC. holds 5.2301 of the shares totaling 4.53 million with a market value of $62.47 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
The most recent transaction is an insider sale by Blackman Samuel C., the company’s HEAD OF R&D. SEC filings show that Blackman Samuel C. sold 30,000 shares of the company’s common stock on Sep 10 ’24 at a price of $14.22 per share for a total of $0.43 million. Following the sale, the insider now owns 1.1 million shares.
Day One Biopharmaceuticals Inc disclosed in a document filed with the SEC on Aug 16 ’24 that Dubow Adam (GENERAL COUNSEL) sold a total of 3,202 shares of the company’s common stock. The trade occurred on Aug 16 ’24 and was made at $14.00 per share for $44825.0. Following the transaction, the insider now directly holds 26928.0 shares of the DAWN stock.
Still, SEC filings show that on Aug 16 ’24, York Charles N II (COO, CFO AND SECRETARY) disposed off 2,633 shares at an average price of $14.00 for $36860.0. The insider now directly holds 232,485 shares of Day One Biopharmaceuticals Inc (DAWN).
